Letter From The Editor

As we move into the ninth year that GLP-1 analogs have been available many of you have taken advantage of this class of medications for your patients. Every day more prescriptions are being filled and patients are learning the value of non-insulin injections for their diabetes. We have seen the …

Now that we have a second SGLT-2 inhibitor on the market we are seeing other companies trying to be the newest "me too’s" on the block. Prescriber acceptance of this class is growing and so it only makes sense that more companies will try to cash in. The newest candidate …

Each year there is a contest to find out which new word added to the dictionary is the most popular. Many of you know that the winner this year was ‘selfie’, a self-taken picture which gets posted on Facebook and other social media sites. But when it comes to our …

I was talking to a physician recently when the topic of SGLT2 inhibitors came up. He spoke about his experience with the drugs and how he felt that a lot of physicians had a negative feeling about the drug because of the chance of UTI’s. He felt that this is …

This past week, I was in an office in St. Petersburg seeing patients and almost all of them were on insulin. In fact they were either on Reg and NPH, or 70/30 lin mix. I have always believed that for most type 2 patients who don’t count carbs or use …

Last Friday, the FDA approved the SGLT2 inhibitor dapaglifozin. This is the second drug in the SGLT2-I class and so now the battle of superiority, dapagliflozin versus canagliflozin, begins. There will also be extra pressure from the DPP4-I companies to downplay the value of this drug class. This week, in …

I am at the annual Consumer Electronics Show in Las Vegas this week and it is easy to see how technology is moving into the healthcare segment. Three years ago, less than 2% of the booths were dedicated to health and wellness — this year, a full 30% of them …

As soon as someone with diabetes goes in the hospital they are usually put on insulin. Since many of the patients have been insulin naive or only on long-acting insulin the introduction of R or analog insulins can often be problematic. In part six of Dr. Stanley Schwartz’s Homerun Slides …

The new year is finally here which means the Affordable Care Act started this past Wednesday. The start-up has been fraught with computer problems, misrepresentations, and half-truths from all sides of the political spectrum. As a medical professional, however, the real question is, will patients be better off? Last Thursday, …

What would you do if you had a patient with type 1 diabetes, unusual fatigue, weight gain, and an A1c 1.3% higher than her previous one? If it was weight gain and a lower A1c it might mean one thing; higher A1c and lower weight would mean something else; but what …